Financial Projections - The company expects a net profit attributable to shareholders of between ¥160 million and ¥190 million for 2025, representing a year-on-year growth of 29.21% to 53.43%[4] - The net profit after deducting non-recurring gains and losses is projected to be between ¥155 million and ¥185 million, reflecting a year-on-year increase of 30.13% to 55.31%[4] - The company anticipates a revenue of ¥837 million for 2025, which indicates a year-on-year growth of approximately 30%[6] - The specific data for the 2025 performance will be detailed in the annual report, and investors are advised to make cautious decisions[10] Product and Service Development - The product matrix includes over 5,000 SKUs, focusing on a comprehensive ecosystem of "products + services + platforms" to meet the full lifecycle needs of global clients[7] - The company is focusing on innovative therapy research, particularly in areas such as in vivo CAR-T/CAR-NK, XDC/ADC, and cell and gene therapy[8] - The company has developed several key products, including AI-engineered recombinant proteins and GMP-grade growth factors for stem cell drug development[8] Supply Chain and Quality Management - The company has established a global supply chain network covering nearly 80 countries and regions, serving over 11,000 end customers, including major pharmaceutical companies[7] - Cost control and quality stability have been enhanced through optimized protein expression efficiency and improved global supply chain management[9] - The company adheres to international quality standards such as ISO9001:2015 and cGMP to enhance operational efficiency and global delivery capabilities[9]
百普赛斯(301080) - 2025 Q4 - 年度业绩预告